- Home
- CYCC vs GUTS Comparison
CYCC vs GUTS Comparison
Compare CYCC & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- GUTS
- Stock Information
- Founded
- CYCC 1992
- GUTS 2010
- Country
- CYCC Malaysia
- GUTS United States
- Employees
- CYCC N/A
- GUTS N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- GUTS
- Sector
- CYCC Health Care
- GUTS
- Exchange
- CYCC Nasdaq
- GUTS NYSE
- Market Cap
- CYCC 61.2M
- GUTS 58.8M
- IPO Year
- CYCC N/A
- GUTS 2024
- Fundamental
- Price
- CYCC $1.63
- GUTS $1.95
- Analyst Decision
- CYCC
- GUTS Buy
- Analyst Count
- CYCC 0
- GUTS 1
- Target Price
- CYCC N/A
- GUTS $10.00
- AVG Volume (30 Days)
- CYCC 191.0K
- GUTS 253.9K
- Earning Date
- CYCC 05-15-2025
- GUTS 05-13-2025
- Dividend Yield
- CYCC 147.24%
- GUTS N/A
- EPS Growth
- CYCC N/A
- GUTS N/A
- EPS
- CYCC N/A
- GUTS N/A
- Revenue
- CYCC $14,000.00
- GUTS $60,000.00
- Revenue This Year
- CYCC $137.21
- GUTS N/A
- Revenue Next Year
- CYCC N/A
- GUTS N/A
- P/E Ratio
- CYCC N/A
- GUTS N/A
- Revenue Growth
- CYCC N/A
- GUTS N/A
- 52 Week Low
- CYCC $1.36
- GUTS $0.87
- 52 Week High
- CYCC $49.34
- GUTS $7.05
- Technical
- Relative Strength Index (RSI)
- CYCC 32.89
- GUTS 56.42
- Support Level
- CYCC $1.36
- GUTS $1.66
- Resistance Level
- CYCC $1.94
- GUTS $1.97
- Average True Range (ATR)
- CYCC 0.43
- GUTS 0.17
- MACD
- CYCC -0.07
- GUTS -0.00
- Stochastic Oscillator
- CYCC 8.31
- GUTS 49.31
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.